Interaction Checker

Dutasteride interactions

Dutasteride (Avodart), a 5-alpha reductase inhibitor has 67 documented interactions across the FDA labels and fact sheets we index: 2 major, 20 moderate, 35 minor, and 10 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (2)

  • Dutasteride and tamsulosin5-alpha reductase inhibitorMajor

    Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride or other 5 alpha-reductase inhibitors [see Adverse Reactions (6.2) ]. (Dutasteride label, Contraindications)

  • Finasteride5-alpha reductase inhibitorMajor

    Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride or other 5 alpha-reductase inhibitors [see Adverse Reactions (6.2) ]. (Dutasteride label, Contraindications)

Moderate interactions (20)

  • Amlodipinedihydropyridine calcium channel blockerModerate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • Amlodipine and atorvastatindihydropyridine calcium channel blockerModerate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • Amlodipine and benazeprildihydropyridine calcium channel blockerModerate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • Amlodipine and olmesartandihydropyridine calcium channel blockerModerate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • Amlodipine and valsartandihydropyridine calcium channel blockerModerate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • Digoxindigitalis glycosideModerate

    Digoxin Dutasteride capsules do not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5 mg/day for 3 weeks [see Clinical Pharmacology (12.3) ]. (Dutasteride label, Drug interactions)

  • Diltiazemcalcium channel blockerModerate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • Felodipinedihydropyridine calcium channel blockerModerate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • Isradipinedihydropyridine calcium channel blockerModerate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • Itraconazoleazole antifungalModerate

    Dutasteride Oxybutynin Sildenafil (for erectile dysfunction) Tadalafil (for erectile dysfunction and benign prostatic hyperplasia) Tolterodine Monitor for adverse reactions. (Itraconazole label, Drug interactions)

  • Lopinavir and ritonavirantiretroviralModerate

    Use with caution in patients taking potent, chronic cytochrome P450 (CYP)3A4 enzyme inhibitors (e.g., ritonavir). (Dutasteride label, Drug interactions)

  • Nicardipinedihydropyridine calcium channel blockerModerate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • Nifedipinedihydropyridine calcium channel blockerModerate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • Nimodipinedihydropyridine calcium channel blockerModerate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • Nirmatrelvir and ritonavirantiviralModerate

    Use with caution in patients taking potent, chronic cytochrome P450 (CYP)3A4 enzyme inhibitors (e.g., ritonavir). (Dutasteride label, Drug interactions)

  • Nisoldipinedihydropyridine calcium channel blockerModerate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • Olmesartan, amlodipine, and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • RitonavirantiretroviralModerate

    Use with caution in patients taking potent, chronic cytochrome P450 (CYP)3A4 enzyme inhibitors (e.g., ritonavir). (Dutasteride label, Drug interactions)

  • Telmisartan and amlodipineangiotensin II receptor blocker (ARB)Moderate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

  • Verapamilcalcium channel blockerModerate

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (Dutasteride label, Drug interactions)

Minor mentions (35)

  • AmiodaroneantiarrhythmicMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • AprepitantCYP3A4 inhibitorMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • AtazanavirantiretroviralMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • CenobamateanticonvulsantMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • CimetidineH2 blockerMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • Clarithromycinmacrolide antibioticMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • CyclosporineimmunosuppressantMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • DarunavirantiretroviralMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • Darunavir and cobicistatantiretroviralMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • DronedaroneantiarrhythmicMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • EfavirenzantiretroviralMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • Efavirenz, lamivudine, and tenofovirantiretroviralMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • Elvitegravir, cobicistat, emtricitabine, and tenofovirantiretroviralMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • Erythromycinmacrolide antibioticMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • EverolimusimmunosuppressantMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • Fluconazoleazole antifungalMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • FosamprenavirantiretroviralMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • FosaprepitantCYP3A4 inhibitorMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • ImatinibCYP3A4 inhibitorMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • IsoniazidantibioticMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • IvacaftorCYP3A4 inhibitorMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • Ketoconazoleazole antifungalMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • LenacapavirantiretroviralMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • MifepristoneCYP3A4 inhibitorMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • Mirabegronbeta-adrenergic agonistMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • NefazodoneantidepressantMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • PalbociclibCYP3A4 inhibitorMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • PerampanelanticonvulsantMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • Posaconazoleazole antifungalMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • RanolazineQT-prolonging drugMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • Suvorexantsedative-hypnoticMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • Tamsulosinalpha blockerMinor

    Coadministration of dutasteride and tamsulosin resulted in similar changes to serum PSA as dutasteride monotherapy. (Dutasteride label, Warnings and precautions)

  • Terazosinalpha blockerMinor

    The effect of administration of tamsulosin or terazosin on dutasteride pharmacokinetic parameters has not been evaluated. (Dutasteride label, Drug interactions)

  • Ticagrelorantiplatelet agentMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

  • Voriconazoleazole antifungalMinor

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasteride label, Drug interactions)

No significant interaction reported (10)

  • Alfuzosinalpha blockerNo interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (Dutasteride label, Drug interactions)

  • Carvedilolbeta blockerNo interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (Dutasteride label, Drug interactions)

  • Cholestyraminebile acid sequestrantNo interaction

    Cholestyramine Administration of a single 5-mg dose of dutasteride capsules followed 1 hour later by 12 g of cholestyramine does not affect the relative bioavailability of dutasteride [see Clinical Pharmacology (12.3) ]. (Dutasteride label, Drug interactions)

  • Doxazosinalpha blockerNo interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (Dutasteride label, Drug interactions)

  • Labetalolbeta blockerNo interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (Dutasteride label, Drug interactions)

  • Phenoxybenzaminealpha blockerNo interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (Dutasteride label, Drug interactions)

  • Phentolaminealpha blockerNo interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (Dutasteride label, Drug interactions)

  • Prazosinalpha blockerNo interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (Dutasteride label, Drug interactions)

  • Silodosinalpha blockerNo interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (Dutasteride label, Drug interactions)

  • WarfarinanticoagulantNo interaction

    Warfarin Concomitant administration of dutasteride capsules 0.5 mg/day for 3 weeks with warfarin does not alter the steady-state pharmacokinetics of the S- or R-warfarin isomers or alter the effect of warfarin on prothrombin time [see Clinical Pharmacology (12.3) ]. (Dutasteride label, Drug interactions)

Check Dutasteride against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.